Aardvark Therapeutics (AARD) News Today

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing renewed negative investor sentiment after multiple law firms publicized a securities class action and encouraged shareholders to seek lead-plaintiff status by October 13, 2026. The legal developments add pressure to a stock that has already declined substantially from its 12-month high.

• Neutral Sentiment: Brokerages currently assign Aardvark a consensus recommendation of “Hold,” indicating limited conviction among analysts while the company’s clinical and legal situation develops. Aardvark Therapeutics Given Consensus Recommendation of Hold
• Negative Sentiment: Several law firms, including Hagens Berman, Kuehn Law, Rosen Law Firm, Levi & Korsinsky, and Faruqi & Faruqi, are soliciting investors in connection with the pending securities class action. The complaints generally allege that Aardvark and certain executives misrepresented the safety and tolerability of its lead candidate, ARD-101, in IPO and subsequent disclosures. Hagens Berman Aardvark Securities Fraud Class Action
• Negative Sentiment: The litigation centers on an alleged disclosure failure surrounding the pause of Aardvark’s Phase 3 HERO trial and the FDA’s subsequent full clinical hold. These events reportedly contributed to a sharp reduction in analyst price targets, with some falling from as high as $29 to approximately $7. AARD Shareholder Alert Regarding Alleged ARD-101 Safety Misstatements
• Negative Sentiment: Pomerantz reported that a federal class action has been filed in the Southern District of California against Aardvark and certain officers and directors under the Securities Act of 1933 and Securities Exchange Act of 1934. Although the allegations have not been proven, the case creates potential legal costs, liability, and reputational risk. Pomerantz Aardvark Class Action Filing